Canaccord analyst Kyle Rose views InMode one of the best risk/reward set-ups in all of MedTech. He noted its preliminary results saw them beat across the top and bottom line and while guidance is within/slightly above expectations, he views its as most likely conservative. Rose maintains his Buy rating and $47 price target in InMode shares.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on INMD:
- InMode raises FY22 adjusted EPS view to $2.38-$2.39 from $2.28-$2.30
- InMode Expects Record Fourth Quarter & Full Year 2022 Financial Results, Q4 Revenue Between $133.2M-$133.4M
- InMode sees Q4 adjusted EPS 73c-74c, consensus 65c
- InMode initiated with an Overweight at Barclays
- InMode call volume above normal and directionally bullish
